Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

InspireMD (NSPR) EPS (Weighted Average and Diluted) (2022 - 2025)

InspireMD filings provide 4 years of EPS (Weighted Average and Diluted) readings, the most recent being -$0.12 for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 33.33% to -$0.12 in Q4 2025 year-over-year; TTM through Dec 2025 was -$0.77, a 0.0% change, with the full-year FY2025 number at -$0.76, changed 0.0% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.12 in Q4 2025 for InspireMD, up from -$0.17 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.12 in Q4 2025 to a low of -$0.6 in Q4 2022.
  • Median EPS (Weighted Average and Diluted) over the past 4 years was -$0.22 (2024), compared with a mean of -$0.29.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): soared 78.33% in 2023 and later tumbled 38.46% in 2024.
  • InspireMD's EPS (Weighted Average and Diluted) stood at -$0.6 in 2022, then soared by 78.33% to -$0.13 in 2023, then crashed by 38.46% to -$0.18 in 2024, then surged by 33.33% to -$0.12 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.12 (Q4 2025), -$0.17 (Q3 2025), and -$0.26 (Q2 2025) per Business Quant data.